Joanna K Metzner - Sadurski, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1325 Spring St, Greenwood, SC 29646 Phone: 864-725-7100 Fax: 864-725-7101 |
Ruiling Xu Yuan, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1325 Spring St, Greenwood, SC 29646 Phone: 864-725-7100 Fax: 864-725-7101 |
News Archive
In the largest study yet to assess the long-term safety and efficacy of the adjustable transobturator male system to treat incontinence in men following invasive prostate treatment, the overall success and dry rates were 90% and 64%, respectively, after a median of 31 months.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
By shedding new light on how cells migrate in the developing brain, researchers at Fred Hutchinson Cancer Research Center also may have found a new mechanism by which other types of cells, including cancer cells, travel within the body.
Before leaving the hospital after childbirth, more women are opting to check one thing off their list: birth control.
› Verified 4 days ago